NasdaqCM:CELCBiotechs
How Investors May Respond To Celcuity (CELC) Expanding VIKTORIA-2 And Pursuing Subcutaneous Gedatolisib
Celcuity Inc. recently expanded its Phase 3 VIKTORIA-2 trial of gedatolisib for advanced HR+/HER2- breast cancer and filed a U.S. patent application for a subcutaneous formulation, following a Type B meeting with the FDA.
By broadening VIKTORIA-2 to both endocrine-resistant and endocrine-sensitive patients and pursuing an injection-based version of gedatolisib, Celcuity is refining how its lead therapy could be used across more real-world treatment settings.
We’ll now examine how expanding...